/Investor DB

Takeda Ventures — 2018 Investments

2 investments dated 2018 · listed companies and verified rows first · show all

Crescendo Biologicscrescendobiologics.comin𝕏Apr 2018 · $70M

Crescendo Biologics develops novel immune cell-enhancing therapeutics for immuno-oncology using its patent-protected Humabody VH platform, a fully human domain technology clinically validated in oncology and immunology.

BiotechHealthtechMedical Devices

Co-investorsAndera PartnersQuan CapitalSofinnova PartnersAstellas Venture Management LLCEMBL VenturesFuture Planet Capital+3 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

ArmaGen

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.